Key Highlights
- PepGen Inc. announces new appointments to its executive team.
- Afsaneh Mohebbi, Ph.D. joins as Senior Vice President, Portfolio and Program Management.
- Dave Borah, CFA appointed as Senior Vice President, Investor Relations and Corporate Communications.
- Key clinical milestones anticipated in the second half of the year.
Source: Business Wire
Notable Quote
- “We are thrilled to welcome Afsaneh and Dave to PepGen. The addition of these two senior team members will enhance our expertise in critical areas of the organization, and we eagerly anticipate their contributions as we prepare for numerous key clinical milestones in the second half of this year. Afsaneh’s extensive experience in advancing candidates from preclinical stages to registration, combined with her strong track record in leading cross-functional teams, will be instrumental in guiding our pipeline of products through the clinic. Dave’s deep industry insights and experience, including his robust network of investors and analysts, will be crucial for maintaining strong communications and relationships with all stakeholders as we develop innovative drug candidates for people living with neuromuscular disorders.” — James McArthur, Ph.D., President and CEO at PepGen
SoHC's Take
The recent appointments of Afsaneh Mohebbi, Ph.D., and Dave Borah, CFA, to PepGen’s executive team mark a significant strategic enhancement as the company positions itself for critical clinical milestones. Dr. Mohebbi’s profound expertise in advancing therapeutic candidates through various development stages and Mr. Borah’s extensive background in investor relations and corporate communications will be invaluable as PepGen continues to develop its innovative oligonucleotide therapies. This move underscores PepGen’s commitment to reinforcing its leadership with seasoned professionals capable of steering the company through its next phase of growth and innovation in the biotechnology sector.
